SG10201703094UA - Therapeutically active pyrazolo-pyrimidine derivatives - Google Patents

Therapeutically active pyrazolo-pyrimidine derivatives

Info

Publication number
SG10201703094UA
SG10201703094UA SG10201703094UA SG10201703094UA SG10201703094UA SG 10201703094U A SG10201703094U A SG 10201703094UA SG 10201703094U A SG10201703094U A SG 10201703094UA SG 10201703094U A SG10201703094U A SG 10201703094UA SG 10201703094U A SG10201703094U A SG 10201703094UA
Authority
SG
Singapore
Prior art keywords
therapeutically active
pyrimidine derivatives
active pyrazolo
pyrazolo
pyrimidine
Prior art date
Application number
SG10201703094UA
Other languages
English (en)
Inventor
Daniel James Ford
Richard Jeremy Franklin
Anant Ramrao Ghawalkar
Helen Tracey Horsley
Qiuya Huang
James Thomas Reuberson
Bart Vanderhoydonck
Original Assignee
Ucb Biopharma Sprl
Katholieke Univ Leuven K U Leuven R&D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201703094U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1223021.5A external-priority patent/GB201223021D0/en
Priority claimed from GBGB1301935.1A external-priority patent/GB201301935D0/en
Application filed by Ucb Biopharma Sprl, Katholieke Univ Leuven K U Leuven R&D filed Critical Ucb Biopharma Sprl
Publication of SG10201703094UA publication Critical patent/SG10201703094UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG10201703094UA 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives SG10201703094UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1223021.5A GB201223021D0 (en) 2012-12-20 2012-12-20 Therapeutic agents
GBGB1301935.1A GB201301935D0 (en) 2013-02-04 2013-02-04 Therapeutic agents

Publications (1)

Publication Number Publication Date
SG10201703094UA true SG10201703094UA (en) 2017-06-29

Family

ID=49886937

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504291SA SG11201504291SA (en) 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives
SG10201703094UA SG10201703094UA (en) 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201504291SA SG11201504291SA (en) 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives

Country Status (33)

Country Link
US (1) US9714248B2 (tr)
EP (1) EP2935269B1 (tr)
JP (1) JP6298830B2 (tr)
KR (1) KR102215490B1 (tr)
CN (1) CN105008360B (tr)
AP (1) AP2015008552A0 (tr)
AU (1) AU2013366480B2 (tr)
BR (1) BR112015014869A2 (tr)
CA (1) CA2893704C (tr)
CL (1) CL2015001752A1 (tr)
CR (1) CR20150379A (tr)
CY (1) CY1120415T1 (tr)
DK (1) DK2935269T3 (tr)
EA (1) EA027752B1 (tr)
ES (1) ES2676515T3 (tr)
HK (1) HK1215705A1 (tr)
HR (1) HRP20181008T1 (tr)
HU (1) HUE038310T2 (tr)
IL (1) IL239163B (tr)
LT (1) LT2935269T (tr)
MX (1) MX2015007774A (tr)
MY (1) MY189182A (tr)
NZ (1) NZ709360A (tr)
PE (1) PE20151767A1 (tr)
PH (1) PH12015501222A1 (tr)
PL (1) PL2935269T3 (tr)
PT (1) PT2935269T (tr)
SA (1) SA515360627B1 (tr)
SG (2) SG11201504291SA (tr)
SI (1) SI2935269T1 (tr)
TN (1) TN2015000285A1 (tr)
TR (1) TR201809140T4 (tr)
WO (1) WO2014096423A1 (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517264D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
JP7306997B2 (ja) 2017-03-20 2023-07-11 ザ・ブロード・インスティテュート・インコーポレイテッド 寄生虫性疾患の処置のための化合物および方法
CN109721531B (zh) * 2017-10-27 2022-07-29 中国科学院合肥物质科学研究院 一种新型的脂质体激酶抑制剂
JP7133023B2 (ja) 2018-01-17 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｉ４ｋｉｉｉベータ阻害剤
CN112752761B (zh) 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
WO2021252505A1 (en) * 2020-06-08 2021-12-16 University Of Vermont And State Agricultural College Arylacetamide analogs of piperazine-[1,2,4]triazolo[4,3-b]pyridazines
KR102673131B1 (ko) * 2020-07-28 2024-06-10 아주대학교산학협력단 신규한 톨-유사 수용체 3/7/9 억제 소분자 화합물
CN116444485B (zh) * 2023-03-30 2024-01-23 广西中医药大学 吡啶基取代不对称脲的非金属催化、免柱层析合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1110649B (de) * 1957-11-22 1961-07-13 Ciba Geigy Verfahren zur Herstellung von 1-Isopropyl-pyrazolo[3, 4-d]pyrimidinen
ATE496035T1 (de) 1998-03-31 2011-02-15 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
TWI259083B (en) * 2002-05-24 2006-08-01 Nat Health Research Institutes Anti-enterovirus compounds
US8362264B2 (en) * 2003-08-22 2013-01-29 Dendreon Corporation Compositions and methods for the treatment of disease associated with Trp-p8 expression
EP1750727A2 (en) * 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
EP1772454A4 (en) * 2004-07-23 2009-02-25 Mitsubishi Tanabe Pharma Corp NITROGENIC CONDENSED BICYCLIC COMPOUND
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
CA2711759A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
EP2923734B1 (en) * 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines

Also Published As

Publication number Publication date
BR112015014869A2 (pt) 2017-07-11
EP2935269B1 (en) 2018-04-11
ES2676515T3 (es) 2018-07-20
EP2935269A1 (en) 2015-10-28
PH12015501222B1 (en) 2015-08-17
TR201809140T4 (tr) 2018-07-23
IL239163B (en) 2018-06-28
LT2935269T (lt) 2018-07-10
EA201500654A1 (ru) 2015-12-30
NZ709360A (en) 2020-01-31
PE20151767A1 (es) 2015-12-11
KR102215490B1 (ko) 2021-02-15
CR20150379A (es) 2015-10-08
SG11201504291SA (en) 2015-07-30
CY1120415T1 (el) 2019-07-10
US9714248B2 (en) 2017-07-25
JP6298830B2 (ja) 2018-03-20
AP2015008552A0 (en) 2015-06-30
EA027752B1 (ru) 2017-08-31
CA2893704A1 (en) 2014-06-26
DK2935269T3 (en) 2018-07-16
TN2015000285A1 (en) 2016-10-03
CN105008360A (zh) 2015-10-28
HK1215705A1 (zh) 2016-09-09
PH12015501222A1 (en) 2015-08-17
MY189182A (en) 2022-01-31
US20160194329A1 (en) 2016-07-07
PT2935269T (pt) 2018-07-16
IL239163A0 (en) 2015-07-30
SA515360627B1 (ar) 2018-05-31
CL2015001752A1 (es) 2016-06-03
AU2013366480A1 (en) 2015-07-09
HUE038310T2 (hu) 2018-10-29
SI2935269T1 (sl) 2018-09-28
AU2013366480B2 (en) 2017-06-22
KR20150111348A (ko) 2015-10-05
CA2893704C (en) 2020-12-15
JP2016503049A (ja) 2016-02-01
MX2015007774A (es) 2015-09-04
WO2014096423A1 (en) 2014-06-26
PL2935269T3 (pl) 2018-09-28
CN105008360B (zh) 2017-09-19
HRP20181008T1 (hr) 2018-08-24

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1215705A1 (zh) 治療活性的吡唑並嘧啶衍生物
HK1208444A1 (en) Pyrrolobenzodiazepines
HK1208217A1 (en) Pyrrolobenzodiazepines
TWI561171B (en) Active compound combinations
EP2868552A4 (en) CONSTRUCTION STRUCTURE FOR VEHICLE CABIN
EP2832453A4 (en) ATOMIZERS
HK1205740A1 (en) Pyrrolotriazinone derivatives
ZA201501500B (en) Electrode padset
AU345615S (en) Electrode
GB201216018D0 (en) Pharmacologically active compounds
GB201411223D0 (en) None
AP2015008347A0 (en) Oxazolidin-2-one-pyrimidine derivatives
EP2902462A4 (en) STRUCTURE BODY
HK1206727A1 (en) Pyrazine derivatives
PL2864328T3 (pl) Związki aktywne farmaceutycznie
EP2940182A4 (en) ROLLER
IL235539A0 (en) liquid sprayer
EP2804853A4 (en) THERAPEUTIC USES
GB201220876D0 (en) Infant mobile
SG11201405989PA (en) Gluten enhancer
GB201410091D0 (en) None
GB201215510D0 (en) Therapeutic cell lines